ライフサイエンスコーパス: subunit vaccine

1 active antigen candidate for a pediatric RSV subunit vaccine.

2 successful immunization with a tuberculosis subunit vaccine.

3 e antigenic responses elicited by a live and subunit vaccine.

4 oundation for the generation of a protective subunit vaccine.

5 on of the molecule might have potential as a subunit vaccine.

6 f Q fever preventatives such as an effective subunit vaccine.

7 of this organism to study its potential as a subunit vaccine.

8 reduce the size of an antigen protein for a subunit vaccine.

9 and thus is a strong candidate for a cholera subunit vaccine.

10 some B-cell epitopes should be included in a subunit vaccine.

11 virus vaccine produced better responses than subunit vaccine.

12 er intranasal immunization with an influenza subunit vaccine.

13 TcpA peptides might serve as immunogens in a subunit vaccine.

14 protection of mice than that obtained with a subunit vaccine.

15 cacy, which may be important in its use as a subunit vaccine.

16 e search for potential components of a multi-subunit vaccine.

17 nts who received an A/Vietnam/1203/2004 H5N1 subunit vaccine.

18 serve as a potential candidate for MERS-CoV subunit vaccines.

19 entified 13 candidate Chlamydia proteins for subunit vaccines.

20 l pathogenesis and to develop anti-Chlamydia subunit vaccines.

21 e motility and for development of sporozoite subunit vaccines.

22 lamydial pathogenesis and the development of subunit vaccines.

23 portunities for production of more effective subunit vaccines.

24 uvant effect of MF59 when combined with H5N1 subunit vaccines.

25 mplications for the design of future protein subunit vaccines.

26 enerated with live, attenuated strains or F1 subunit vaccines.

27 e useful for diagnostics and next-generation subunit vaccines.

28 for inclusion in future human orthopoxvirus subunit vaccines.

29 have proven more efficacious than killed or subunit vaccines.

30 in a more authentic conformation than other subunit vaccines.

31 regions within the GbpB sequence for use in subunit vaccines.

32 rriers for optimizing the immune response to subunit vaccines.

33 al peptide libraries is a promising route to subunit vaccines.

34 roach can be utilized for the development of subunit vaccines.

35 ines, auxotrophic vaccines, DNA vaccines and subunit vaccines.

36 tems enable rapid and scalable production of subunit vaccines.

37 cellular immunity to gH and gL within future subunit vaccines.

38 egimens are recommended for all prophylactic subunit vaccines.

39 be possible to develop effective single-dose subunit vaccines.

40 igenic ORFs that may be useful components of subunit vaccines.

41 onsidered in the design of future Salmonella subunit vaccines.

42 es, including vectored, live attenuated, and subunit vaccines.

43 thus will guide rational design of MERS-CoV subunit vaccines.

44 taneously increase the potency and safety of subunit vaccines.

45 uired for the rational design of ricin toxin subunit vaccines.

46 for the development of safe and efficacious subunit vaccines, a direct comparison of the immunogenic

47 For subunit vaccines, adjuvants play a key role in shaping i

48 Booster vaccination with a subunit vaccine (Ag85B-ESAT-6+CAF01) expanded IL-2(+) CD

49 the leading candidate Ags for inclusion in a subunit vaccine against blood-stage malaria.

50 the known entry properties of BoNT/A, an HCR subunit vaccine against BoNT/A that contained the point

51 usion protein has significant potential as a subunit vaccine against BVDV infection.

52 Our results provide a path to a subunit vaccine against dengue virus and have implicatio

53 a protective immune response to a candidate subunit vaccine against DENV-2.

54 l safety and immunogenicity of a recombinant subunit vaccine against enterotoxigenic Escherichia coli

55 The results of a clinical trial of a subunit vaccine against genital herpes were recently rep

56 antigen combination as a promising candidate subunit vaccine against human leishmaniasis.

57 e findings serve as a basis for developing a subunit vaccine against schistosomiasis.

58 may be explored as potential components of a subunit vaccine against sexually transmitted diseases ca

59 c domain (pB5), an attractive component of a subunit vaccine against smallpox.

60 ctive candidate for inclusion in a universal subunit vaccine against T. pallidum infection.

61 is a potential candidate for inclusion in a subunit vaccine against TB.

62 gment of tetanus toxin that can be used as a subunit vaccine against tetanus.

63 Initial laboratory trials of an experimental subunit vaccine against Theileria parva based on the 67-

64 In the first phase 1 study of any candidate subunit vaccine against tuberculosis, recombinant modifi

65 ce were prioritized for the development of a subunit vaccine against tuberculosis.

66 n the identification of a candidate Ag for a subunit vaccine against tuberculosis.

67 the inclusion of CTB in the development of a subunit vaccine against V. cholerae.

68 analytic vaccinology for the development of subunit vaccines against complex pathogens.

69 way may provide a general delivery route for subunit vaccines against many mucosal pathogens.

70 utilize attenuated live virus as opposed to subunit vaccines against ocular HSV-1 infection.

71 s contrast with the utility of type IV pilin subunit vaccines against other infectious diseases and h

72 human T cell Ags suitable to be included in subunit vaccines against tuberculosis.

73 to facilitate the production and delivery of subunit vaccines against various pathogenic bacteria and

74 Although inactivated viruses and subunit vaccines alleviate many of these concerns, they

75 t was not detected upon vaccination with the subunit vaccine alone.

76 ombination is no more protective than either subunit vaccine alone.

77 site of S1 could be an attractive target for subunit vaccine and drug development.

78 nogenicity to a trivalent influenza seasonal subunit vaccine and to tetanus toxoid (TT) in mouse.

79 A major obstacle to development of subunit vaccines and diagnostic reagents for tuberculosi

80 S enables rational design of next-generation subunit vaccines and functional and medicinal chemical i

81 implications for the design of CD8(+) T cell subunit vaccines and in particular raise the exciting pr

82 Several subunit vaccines and live attenuated virus vaccines are

83 ne proteins are candidates for orthopoxvirus subunit vaccines and potential targets for therapeutic a

84 HCI) is a crucial step in the development of subunit vaccines and prediction of such binding could gr

85 These materials should enable a range of subunit vaccines and provide new possibilities for thera

86 o achieve because of the limited efficacy of subunit vaccines and the safety concerns about live viru

87 r a physiological route of inoculation and a subunit vaccine approach elicited MCMV-specific and prot

88 No subunit vaccine approach showed efficacy in mice followi

89 This is the first demonstration that a subunit vaccine approach to smallpox-monkeypox immunizat

90 5HA vaccine, which is based on a traditional subunit vaccine approach, HAd-H5HA vaccine induced a thr

91 Current subunit vaccine approaches do not provide efficient long

92 iven their admirable safety records, protein subunit vaccines are attractive for widespread immunizat

93 Recombinant subunit vaccines are easier to manufacture with a relati

94 Current subunit vaccines are incapable of inducing Ag-specific C

95 Antigens in modern subunit vaccines are largely soluble and poorly immunoge

96 to increase adaptive responses to influenza subunit vaccines are not well characterized.

97 Subunit vaccines are often less immunogenic than whole p

98 Heat-inactivated formulations and subunit vaccines are safer but less potent and require a

99 hat additional control strategies, such as a subunit vaccine, are required to block transmission and

100 opening the possibility of orally delivered subunit vaccines, as has the ability to modify the immun

101 t coadministration of IL-12 and an influenza subunit vaccine at birth enhances the protective efficac

102 the utility of a newly developed recombinant subunit vaccine based on the HeV attachment (G) glycopro

103 evaluation of the efficacy of a recombinant subunit vaccine based on the RVFV Gn and Gc glycoprotein

104 inical trials in young women have shown that subunit vaccines based on human papillomavirus (HPV) 16

105 Subunit vaccines based on recombinant proteins can suffe

106 This Review examines prophylactic HPV subunit vaccines based on the ability of the viral L1 ca

107 Subunit vaccines based on the herpes simplex virus 2 (HS

108 Therapeutic subunit vaccines based on tumor-associated antigens (TAA

109 murium are potentially useful for developing subunit vaccines because of high immunogenicity and prot

110 ting of a threatened pandemic before matched subunit vaccines become available.

111 ous mucosal priming followed by a parenteral subunit vaccine booster paves the way for clinical trial

112 ditary hemochromatosis may be protected with subunit vaccines but should not be exposed to live-atten

113 ant molecules have been developed to enhance subunit vaccines, but in general these materials have fa

114 re, the gC-2 subunit antigen enhances a gD-2 subunit vaccine by stimulating a CD4+ T-cell response, b

115 easibility of producing safe and inexpensive subunit vaccines by using plant production systems.

116 ether (re)vaccination with the adjuvanted HZ subunit vaccine candidate (HZ/su) induced comparable imm

117 ese results suggest that FspA1 may be a good subunit vaccine candidate against C. jejuni disease.

118 se features suggest that NucA is a potential subunit vaccine candidate against NTHi disease.

119 d subcutaneously with the glycoprotein-based subunit vaccine candidate and then subjected to heterolo

120 genesis and potentially optimizing Pgp3 as a subunit vaccine candidate antigen.

121 RH5 is a leading subunit vaccine candidate because anti-RH5 antibodies in

122 d varicella-zoster virus glycoprotein E (gE) subunit vaccine candidate for herpes zoster is in develo

123 y virus, type 1 (HIV-1), currently, only one subunit vaccine candidate has reached phase 3 of clinica

124 cine production systems to generate a dengue subunit vaccine candidate in tobacco.

125 ke conformation and is a potential prefusion subunit vaccine candidate.

126 Glycoprotein B (gB) has emerged as a subunit-vaccine candidate for congenital cytomegalovirus

127 litate the selection of promising chlamydial subunit vaccine candidates for further evaluation.

128 nated by the subunit approach; however, many subunit vaccine candidates have had limited efficacy in

129 stability of previous RSV fusion protein (F) subunit vaccine candidates have hampered vaccine develop

130 Inclusion of multiple Ag variants in subunit vaccine candidates is one strategy that has aime

131 model, as suboptimal dosing of several RSV F subunit vaccine candidates led to the priming for ERD.

132 Most subunit vaccine candidates tested in clinical trials hav

133 n this study, we developed and evaluated two subunit vaccine candidates that consisted of the same pr

134 gens have become important components of the subunit vaccine candidates that we are currently develop

135 Live attenuated and subunit vaccine candidates, which are under clinical eva

136 OPS to facilitate the synthesis of glanders subunit vaccine candidates.

137 Recombinant subunit-vaccine candidates offer potential alternatives,

138 good road map for guiding the development of subunit vaccines capable of inducing the same.

139 that immunization with a licensed influenza subunit vaccine coated on metal microneedles can activat

140 ressed directly, it is a promising potential subunit vaccine component.

141 hogen-specific Abs are a potential source of subunit vaccine components.

142 A subunit vaccine composed of protective vaccinia virus pr

143 We developed a subunit vaccine composed of the NAb targets gD and gB an

144 tilizing non-catalytic full-length BoNT or a subunit vaccine composed of the receptor binding domain

145 To overcome this issue, subunit vaccines composed of VV envelope proteins from b

146 s, have been mostly replaced by acellular or subunit vaccines composed of well-defined, purified anti

147 infection and use it in the evaluation of a subunit vaccine comprised of soluble G glycoprotein (sG)

148 Subunit vaccines comprised of glycoprotein D (gD-2) fail

149 s become important to the development of new subunit vaccines consisting of isolated antigens.

150 Many therapeutic proteins and protein subunit vaccines contain heterologous trimerization doma

151 ies of a herpes simplex virus type 2 (HSV-2) subunit vaccine containing glycoprotein D in HSV-discord

152 ponse to a herpes simplex virus (HSV) type 2 subunit vaccine containing recombinant glycoproteins B (

153 ing a Th1 response and indicate that while a subunit vaccine containing the ML0276 protein may be use

154 -2 clinical trials involving older adults, a subunit vaccine containing varicella-zoster virus glycop

155 us immunization of C57BL/6 mice with protein subunit vaccines containing one or two of these lipoprot

156 Subunit vaccines containing recently discovered clusters

157 (nonpigmented) strains and immunization with subunit vaccines containing recombinant low-calcium-resp

158 Subunit vaccines containing universal tumor associated a

159 suggests that a combination of CSP and TRAP subunit vaccines could enhance protection against malari

160 This implication has a bearing on subunit vaccine design strategies and understanding fail

161 ectin epitopes to be studied in an amebiasis subunit vaccine designed to elicit mucosal immunity mimi

162 allenge with HSV-2 than that obtained with a subunit vaccine, despite inducing lower titers of HSV-2

163 accine design through attenuation as well as subunit vaccine development continue to move forward to

164 zing antibodies and potential candidates for subunit vaccine development, but our understanding of th

165 fied as potential candidates for recombinant subunit vaccine development.

166 alizing antibodies, has become the focus for subunit vaccine development.

167 The advances in subunit vaccines development have intensified the search

168 ce interval [CI], 58.5%-90.3%) compared with subunit vaccine effectiveness of 44.2% (95% CI, -11.8% t

169 rast to conventional vaccines, DNA and other subunit vaccines exclusively utilize host cell molecules

170 elopment in the liver, and immunization with subunit vaccines expressing the respective antigenic moi

171 gue against inclusion of LppQ-N' in a future subunit vaccine for CBPP.

172 to be incorporated into an effective defined subunit vaccine for cholera.

173 oved antigen for plant-based expression of a subunit vaccine for hepatitis B virus.

174 of this antigen as a possible component of a subunit vaccine for M.tuberculosis.

175 Development of a subunit vaccine for Mycobacterium tuberculosis (Mtb) dep

176 Development of a subunit vaccine for Mycobacterium tuberculosis (Mtb) is

177 A subunit vaccine for Plasmodium falciparum malaria will n

178 The development of a subunit vaccine for smallpox represents a potential stra

179 d a polyethylene glycol (PEG) hydrogel-based subunit vaccine for the delivery of an antigenic peptide

180 promising candidates for the development of subunit vaccines for immunization against melioidosis.

181 Development of subunit vaccines for malaria that elicit a strong, long-

182 were immunized with H1N1/A/California/7/2009 subunit vaccines, formulated with different adjuvants in

183 n the mechanistic basis of the SA-4-1BBL/SVN subunit vaccine formulation in a lung carcinoma model an

184 r to peptides 4, 5, and 6 could be used in a subunit vaccine formulation.

185 New subunit vaccine formulations with increased potency are

186 In the present study, a candidate subunit vaccine, GEN-003/MM-2, was evaluated for its abi

187 Although monomeric HIV envelope subunit vaccines (gp120) have induced high-titer antibod

188 ulmonary tuberculosis and vaccination with a subunit vaccine (H56) induced poor protection against it

189 edge, this is the first time a protein based subunit vaccine has been able to induce CD8+ T cell agai

190 ion against many infectious diseases, but no subunit vaccine has induced CD8(+) T cells that correlat

191 This is the first time a subunit vaccine has shown a significant reduction in ocu

192 The progress toward subunit vaccines has been limited by their poor immunoge

193 osal immune system of the genital tract with subunit vaccines has failed to induce potent and durable

194 CS-based subunit vaccines have been hampered by suboptimal immuno

195 Subunit vaccines have been investigated in over 1000 cli

196 Previous human trials of subunit vaccines have been unsuccessful.

197 Subunit vaccines have failed, to date, to fully protect

198 Here we provide an overview of subunit vaccine history as it pertains to instigating T

199 genicity and safety of an investigational HZ subunit vaccine (HZ/su).

200 rtain sF constructs could serve as potential subunit vaccine immunogens against henipaviruses and als

201 Success of the recombinant subunit vaccine in AGMs provides pivotal data in support

202 The success of this new subunit vaccine in nonhuman primates provides critical d

203 In an attempt to generate a subunit vaccine in this experimental disease model, euka

204 he recently completed clinical trial of a gB subunit vaccine in which the rate of HCMV infection was

205 The use of DNA and protein subunit vaccines in animals provides an opportunity to i

206 Despite the consistent failures of HSV subunit vaccines in clinical trials spanning the past 28

207 Current antiplague subunit vaccines in development for utilization in human

208 Our data suggest that a subunit vaccine incorporating bacterially expressed IMV-

209 cines present safety challenges, and protein subunit vaccines induce primarily antibody responses.

210 hereas vaccination of mice with an influenza subunit vaccine induced moderate virus-specific IgG1, va

211 Development of an antimalarial subunit vaccine inducing protective cytotoxic T lymphocy

212 Nanoparticle-based vaccines, including subunit vaccines involving synthetic and/or natural poly

213 ted recombinant varicella zoster virus (VZV) subunit vaccine is being developed for the prevention of

214 n ocular herpes simplex virus type 1 (HSV-1) subunit vaccine is the identification of an efficient, s

215 A subunit vaccine is the only option in the absence of lon

216 One candidate for the development of a subunit vaccine is the Y. pestis virulence (V) antigen,

217 of a trivalent P2-VP8 (P[4], P[6], and P[8]) subunit vaccine is underway at three sites in South Afri

218 One major barrier to the use of subunit vaccines is the requirement for T helper cell ep

219 om adults who received a dose of inactivated subunit vaccine (ISV) targeting monovalent 2009 pandemic

220 ation of PIKA with a poorly immunogenic H5N1 subunit vaccine led to antigen sparing and quantitative

221 vaccines in immunocompromised individuals, a subunit vaccine may be an appropriate alternative.

222 Subunit vaccines may be at a disadvantage because they m

223 Our results suggest that AMA1 subunit vaccines may be highly effective when presented

224 st that although soluble oligomeric envelope subunit vaccines may elicit neutralizing antibody respon

225 nduced by Vi Ag, and targeting non-Vi Ags as subunit vaccines may offer an attractive strategy to aug

226 Thus, protein subunit vaccines may prime a unique subset of differenti

227 An effective subunit vaccine must traffic to lymph nodes (LNs), activ

228 Effective subunit vaccines must elicit strong CD4(+) T cell respon

229 Synthetic subunit vaccines need to induce CD8(+) cytotoxic T cell

230 Because nonreplicating subunit vaccines offer the possibility of formulation fo

231 Viral subunit vaccines often contain immunodominant non-neutra

232 achinery and for engineering next-generation subunit vaccines or inhibitors against this medically im

233 We conclude that the subunit vaccine platform represents a promising strategy

234 Typhi outer-membrane protein C- and F-based subunit vaccine (porins).

235 Most subunit vaccines primarily generate humoral immune respo

236 e oral vaccines and as "reagent strains" for subunit vaccine production in a safe and economical mann

237 results show that a receptor binding domain subunit vaccine protects against serotype variants of Bo

238 that may explain the limited success of most subunit vaccine protocols designed to preferentially ind

239 ore effective than the corresponding protein subunit vaccine, regardless of adjuvant.

240 , optimal timing to boost BCG-immunity using subunit vaccines remains unclear in clinical trials.

241 Most subunit vaccines require adjuvants in order to induce pr

242 However, TAA-based subunit vaccines require potent adjuvants for therapeuti

243 Highly purified subunit vaccines require potent adjuvants in order to el

244 Malaria subunit vaccines require potent adjuvants, as they lack

245 A candidate ricin subunit vaccine (RiVax) consisting of a recombinant atte

246 al immunization with B. melitensis LPS-GBOMP subunit vaccine significantly protects mice against intr

247 A target of subunit vaccine strategies is the poxvirus protein A33,

248 No subunit vaccine strategy alone has generated demonstrabl

249 and associated pathogenesis and an effective subunit vaccine strategy appears achievable.

250 In subunit vaccines, strong CD8(+) T-cell responses are des

251 ance: Several herpes simplex virus 2 (HSV-2) subunit vaccine studies have been conducted in human sub

252 s (human or not) to prepare purified protein subunit vaccines, such as for HIV, and the use of human

253 However, this and other subunit vaccines, such as virus-vectored thrombospondin-

254 DNA or viruses, live attenuated pathogens or subunit vaccines targeted and enhanced using adjuvants.

255 t interest in the development of Ab-inducing subunit vaccines targeting infections, including HIV, ma

256 The best candidate is a subunit vaccine termed RTS,S but this provides only part

257 idate antigen for inclusion in a multivalent subunit vaccine that attempts to block HSV-2 immune evas

258 Immunization of Hjv(-/-) mice with a subunit vaccine that blocks Y. pestis type III secretion

259 genic advantage associated with the multiple subunit vaccine that induced a higher frequency of Th1 c

260 We designed an amebiasis subunit vaccine that is constructed by using four peptid

261 rticles (VLPs) represent a specific class of subunit vaccine that mimic the structure of authentic vi

262 solates into hybrid Coa and vWbp proteins, a subunit vaccine that provided protection against challen

263 Subunit vaccines that combine peptide or protein Ags wit

264 y and has moved from whole microorganisms to subunit vaccines that contain only their antigenic prote

265 These results support efforts to develop subunit vaccines that effectively elicit high levels of

266 exists, much effort is currently focused on subunit vaccines that elicit CD8 T cell responses direct

267 fficient discrete T-cell antigens to develop subunit vaccines that produce sterile immunity.

268 cells affect the topical/mucosal delivery of subunit vaccines that stimulate the ocular mucosal immun

269 Here we review polysaccharide-conjugate and subunit vaccines that were designed to prevent S. aureus

270 f microneedle delivery of licensed influenza subunit vaccines, that could be beneficial in increasing

271 We determined whether a subunit vaccine to a portion of PfEMP1 could induce prot

272 accination against RSV and influenza using a subunit vaccine to enhance immunity and neutralizing ant

273 uggest continuing the development of an HgbA subunit vaccine to prevent chancroid.

274 ex virus type 2 (HSV-2) glycoprotein D (gD2) subunit vaccine to prevent genital herpes.

275 ghly effective, and broad-spectrum RBD-based subunit vaccine to prevent MERS-CoV infection.

276 ned if the ML0276 protein could be used in a subunit vaccine to provide protection against experiment

277 uggesting that it could serve as a potential subunit vaccine to provide variant cross-specific immuni

278 uide the rational design of highly effective subunit vaccines to combat MERS-CoV and other life-threa

279 The development of protein subunit vaccines to combat some of the world's deadliest

280 y for the design of unique defined-structure subunit vaccines to confer comprehensive protection via

281 The first subunit vaccines to enter clinical trails were safe and

282 ions of inactivated whole-virus and envelope subunit vaccines to equine infectious anemia virus (EIAV

283 general application to a spectrum of protein subunit vaccines to increase immunogenicity without the

284 ay be used in conjunction with protein-based subunit vaccines to maximize the efficacy of a human mal

285 However, many subunit vaccines under development fail to generate robu

286 s-specific epitopes, our data suggest that a subunit vaccine using the variola virus homologues might

287 nses that are unparalleled by a glycoprotein subunit vaccine vis-a-vis Ab persistence and host protec

288 A Hendra virus attachment (G) glycoprotein subunit vaccine was tested in nonhuman primates to asses

289 In this study, HZ/su adjuvanted subunit vaccine was well tolerated and more immunogenic

290 une correlates of adjuvanticity to influenza subunit vaccine, we investigated the gene signatures ind

291 body responses to one dose of whole virus or subunit vaccine were poor, fulfilling none of the criter

292 ination with adjuvants as well as adjuvanted subunit vaccines were successful in the induction of NAb

293 Specifically, well-characterized subunit vaccines, which are designed to generate antitum

294 simplex virus type 2 (HSV-2) glycoprotein-D-subunit vaccine with alum and 3-O-deacylated-monophospho

295 , sera from individuals vaccinated with H5N1 subunit vaccine with moderate anti-H5N1 neutralizing ant

296 light the importance of properly formulating subunit vaccines with effective adjuvants for use agains

297 h live, attenuated (nonpigmented) strains or subunit vaccines with F1 (Caf1) antigen is considered ef

298 isplayed impaired T cell priming to the H1N1 subunit vaccine, with concomitant reduction in recall me

299 re, many new types of vaccines, particularly subunit vaccines, with improved safety and efficacy for

300 s to determine whether adding gC-2 to a gD-2 subunit vaccine would improve protection by producing an